November 9th, 2010
Intensive Statin Therapy Examined in Meta-Analysis and SEARCH Trial
Larry Husten, PHD
A new meta-analysis and a large clinical trial shed new light on the additive effects of intensive statin therapy over standard therapy. The meta-analysis from the Cholesterol Treatment Trialists’ Collaboration and the results from SEARCH (Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine) are published online in the Lancet. The meta-analysis examined individual […]
October 13th, 2010
Sequencing Study Identifies Gene Mutations Tied to Hypolipidemia
Larry Husten, PHD
By sequencing all protein-coding regions of the genome in two people with combined hypolipidemia, researchers have identified a gene that may lead to a new method to lower LDL cholesterol. The report by Kiran Musunuru and colleagues, published in the New England Journal of Medicine, has its origins in a study started in 1994 of […]
July 22nd, 2010
HDL and Residual Risk: A Surprising Finding in JUPITER
Larry Husten, PHD
CardioExchange welcomes Dr. Paul Ridker to answer questions about his recent paper in the Lancet, which analyzed data from JUPITER and found that HDL may not predict residual risk in patients on high-dose statins who reach very low LDL levels such as those achieved in the treatment group in JUPITER. The findings may surprise some readers, though […]
NEJM Journal Watch — Recent Cardiology Articles- Sex-Based Disparity in CABG Outcomes: Are We Moving Toward Parity?
- Can Genetic and Social Risk Scores Improve Cardiac Risk Prediction?
- Extensive Ablation vs. Pulmonary Vein Isolation in Persistent Atrial Fibrillation
- Can a Novel Stent Design Improve Long-Term Outcomes of Percutaneous Coronary Intervention?
- Are Angiographically-Derived Coronary Physiology Measurements Ready for Use in the Cath Lab?